VEGFA and neoplasm: Bevacizumab, a humanized monoclonal antibody against VEGF-A, can bind to VEGF-A and inhibit its activity through suppressing receptor binding, endothelial cell proliferation, and neovasculature formation, thus decelerating tumor growth (Table 1) (Figure 2) [34–36].